Testing a New Treatment for Early-Onset Alzheimer's Disease

This study is testing how well lecanemab works for people under 65 years old who have early-onset Alzheimer's disease and a family history of the condition. Lecanemab is designed to reduce the buildup of a protein in the brain that may be linked to Alzheimer's disease. Researchers want to understand how well this medication works and whether genetics and family history affect how it helps patients.

Most Alzheimer's research focuses on people diagnosed later in life, but some people develop symptoms much earlier—in their 40s, 50s, or early 60s. This medication may be helpful for these younger patients, especially those with a family history of the disease, but we need real-world evidence to understand how well it truly works for them.